Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 9/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.33 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.33 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.33 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.33 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.33 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.33 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.33 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.33 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.33 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555703 | 0.87 | ALDH1A1 (0.38) | CNR1TP53MDM2GCGRCNR2 | |
| SCHEMBL3553263 | 0.85 | ALDH1A1 (0.37) | CNR1TP53MDM2SHMT1SHMT2 | |
| SCHEMBL2850853 | 0.83 | MMP2 (0.38) | MMP2MMP3CNR1ADCY6ADCY3 | |
| SCHEMBL3547208 | 0.81 | ALDH1A1 (0.40) | CNR1TP53MDM2GCGRCNR2 | |
| SCHEMBL3550717 | 0.78 | MAPT (0.44) | CNR1TP53MDM2GCGRCNR2 | |
| SCHEMBL2846413 | 0.77 | CNR1 (0.42) | MMP2MMP3CNR1ADCY6ADCY3 | |
| SCHEMBL3552068 | 0.77 | CNR1 (0.41) | CNR1TP53MDM2CNR2 | |
| SCHEMBL3551713 | 0.75 | CNR1 (0.39) | CNR1CNR2 | |
| SCHEMBL3548754 | 0.75 | CNR1 (0.40) | CNR1TP53MDM2SHMT1SHMT2 | |
| SCHEMBL5300506 | 0.74 | DPP4 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674821-B2 | N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea) derivatives as cannabinoid CB1 receptor antagonists | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | claimed |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | claimed |
| EP-1833812-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL]AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2007-09-19 | — | — | EP | claimed |
| WO-2006070106-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | WO | claimed |
| US-7674821-B2 | N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea) derivatives as cannabinoid CB1 receptor antagonists | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
| EP-1833812-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL]AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006070106-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR1, CNR2, UTS2R | MMP2 4789/4885MMP3 4715/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.